EMA first to review data package of Lundbeck multimodal antidepressant vortioxetine
This article was originally published in Scrip
Executive Summary
Lundbeck's marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the multimodal antidepressant, vortioxetine, has been accepted for review, representing "the first European centralised filing of a novel antidepressant treatment since 2007", it noted.